MDT

84.09

-0.06%↓

VEEV

226.15

+0.17%↑

A

105.84

-0.02%↓

WBA

10.99

+0.09%↑

CHE

550.42

-2.1%↓

MDT

84.09

-0.06%↓

VEEV

226.15

+0.17%↑

A

105.84

-0.02%↓

WBA

10.99

+0.09%↑

CHE

550.42

-2.1%↓

MDT

84.09

-0.06%↓

VEEV

226.15

+0.17%↑

A

105.84

-0.02%↓

WBA

10.99

+0.09%↑

CHE

550.42

-2.1%↓

MDT

84.09

-0.06%↓

VEEV

226.15

+0.17%↑

A

105.84

-0.02%↓

WBA

10.99

+0.09%↑

CHE

550.42

-2.1%↓

MDT

84.09

-0.06%↓

VEEV

226.15

+0.17%↑

A

105.84

-0.02%↓

WBA

10.99

+0.09%↑

CHE

550.42

-2.1%↓

Search

Kura Oncology Inc

Deschisă

SectorSănătate

6.38 0.95

Rezumat

Modificarea prețului

24h

Curent

Minim

6.11

Maxim

6.43

Indicatori cheie

By Trading Economics

Venit

35M

-19M

Vânzări

54M

54M

EPS

-0.22

Marjă de profit

-35.664

Angajați

192

EBITDA

43M

-17M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+284.14% upside

Dividende

By Dow Jones

Următoarele câștiguri

1 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-114M

499M

Deschiderea anterioară

5.43

Închiderea anterioară

6.38

Scor tehnic

By Trading Central

Încredere

Very Strong Bullish Evidence

Kura Oncology Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 apr. 2025, 23:54 UTC

Acțiuni populare

Stocks to Watch: Alphabet, Intel, AppFolio

24 apr. 2025, 23:51 UTC

Market Talk

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 apr. 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 apr. 2025, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 apr. 2025, 23:37 UTC

Top știri

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 apr. 2025, 23:36 UTC

Top știri

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24 apr. 2025, 23:13 UTC

Top știri
Câștiguri

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 apr. 2025, 23:09 UTC

Top știri

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 apr. 2025, 23:02 UTC

Achiziții, Fuziuni, Preluări

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 apr. 2025, 23:02 UTC

Achiziții, Fuziuni, Preluări

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 apr. 2025, 22:51 UTC

Top știri
Achiziții, Fuziuni, Preluări

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 apr. 2025, 22:48 UTC

Top știri

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 apr. 2025, 22:47 UTC

Market Talk

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 apr. 2025, 22:38 UTC

Market Talk
Câștiguri

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 apr. 2025, 22:24 UTC

Câștiguri

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 apr. 2025, 22:24 UTC

Câștiguri

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 apr. 2025, 22:24 UTC

Market Talk
Câștiguri

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 apr. 2025, 22:23 UTC

Câștiguri

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 apr. 2025, 22:11 UTC

Market Talk
Câștiguri

Global Equities Roundup: Market Talk

24 apr. 2025, 22:11 UTC

Market Talk
Câștiguri

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 apr. 2025, 22:09 UTC

Top știri
Câștiguri

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 apr. 2025, 22:00 UTC

Market Talk
Câștiguri

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 apr. 2025, 21:39 UTC

Top știri

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 apr. 2025, 21:24 UTC

Top știri
Câștiguri

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 apr. 2025, 21:24 UTC

Top știri
Câștiguri

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 apr. 2025, 21:23 UTC

Top știri
Câștiguri

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 apr. 2025, 21:04 UTC

Câștiguri

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 apr. 2025, 21:03 UTC

Câștiguri

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 apr. 2025, 21:03 UTC

Câștiguri

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 apr. 2025, 21:02 UTC

Câștiguri

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Comparație

Modificare preț

Kura Oncology Inc Așteptări

Obiectiv de preț

By TipRanks

284.14% sus

Prognoză pe 12 luni

Medie 24.7 USD  284.14%

Maxim 40 USD

Minim 10 USD

În baza a 13 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruKura Oncology Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

13 ratings

10

Cumpărare

3

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

5.77 / 6.6Suport & Rezistență

Termen scurt

Very Strong Bullish Evidence

Termen mediu

Bullish Evidence

Termen lung

Weak Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.